Association between rotavirus gastroenteritis and intussusception: suggested evidence from a retrospective study in claims databases in the United States.


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
02 01 2021
Historique:
pubmed: 2 7 2020
medline: 22 6 2021
entrez: 2 7 2020
Statut: ppublish

Résumé

The etiology of intussusception (IS), a serious gastrointestinal obstruction, remains unclear. Limited evidence suggests a role for viral infection. We investigated the risk of IS after rotavirus gastroenteritis (RV GE) in the first year of life. In this retrospective, self-controlled case series (SCCS), we assessed the risk of IS after RV GE using data from United States administrative claims databases. Incidence rate ratios (IRR) of IS were calculated for the 7- and 21-day risk periods after RV GE (main analysis) or after fracture (sensitivity analysis). A total of 290,912,068 subjects were screened; 42 presented claims for RV GE and IS, and 66 for fracture and IS. The IRRs of IS after RV GE were 79.6 (95% confidence interval, CI: 38.6-164.4) and 25.5 (95% CI: 13.2-49.2) in the 7- and 21-day risk periods. The sensitivity analysis showed an association between IS and fracture for both periods, suggesting potential confounding. Post-hoc analyses did not confirm the association between fracture and IS but suggested a potential association between RV GE and IS. A temporal association between RV GE and IS was detected using claims databases. Due to some limitations of the data sources, this association should be further investigated.

Identifiants

pubmed: 32609045
doi: 10.1080/21645515.2020.1770514
pmc: PMC7872044
doi:

Substances chimiques

Rotavirus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

269-277

Références

Stat Med. 2018 Feb 20;37(4):643-658
pubmed: 29094391
Pediatrics. 2005 Jan;115(1):78-82
pubmed: 15629984
J Pediatr. 2010 May;156(5):761-5
pubmed: 20138300
J Clin Virol. 2014 Dec;61(4):579-84
pubmed: 25464971
Epidemiol Infect. 2011 Dec;139(12):1805-17
pubmed: 21849099
Vaccine. 2004 Jan 26;22(5-6):569-74
pubmed: 14741146
Eur Respir J. 2018 Mar 29;51(3):
pubmed: 29563170
Pediatrics. 2008 May;121(5):e1125-32
pubmed: 18450856
J Infect Dev Ctries. 2013 Jan 15;7(1):28-35
pubmed: 23324817
Pediatr Emerg Care. 2012 Sep;28(9):842-4
pubmed: 22929138
Vaccine. 2004 May 7;22(15-16):2064-70
pubmed: 15121324
Vaccine. 2012 Jun 29;30(31):4585-7
pubmed: 22580356
Stat Med. 2006 May 30;25(10):1768-97
pubmed: 16220518
BMJ. 2016 Sep 12;354:i4515
pubmed: 27618829
PLoS One. 2013 Jul 22;8(7):e68482
pubmed: 23894308
Pediatr Infect Dis J. 2015 Jul;34(7):763-8
pubmed: 26069948
Int J Epidemiol. 2019 Aug 1;48(4):1316-1326
pubmed: 30879038
Clin Colon Rectal Surg. 2017 Feb;30(1):30-39
pubmed: 28144210
J Med Virol. 1978;2(3):265-69
pubmed: 212529
Hum Vaccin Immunother. 2017 Feb;13(2):445-449
pubmed: 28075671
Pediatrics. 2016 Sep;138(3):
pubmed: 27558938
Hum Vaccin Immunother. 2018 Jul 3;14(7):1782-1790
pubmed: 29533129
Am J Dis Child. 1992 Nov;146(11):1331-3
pubmed: 1415074
Vaccine. 2019 Jul 26;37(32):4587-4593
pubmed: 30851968
J Infect Dis. 2012 Dec 1;206(11):1652-9
pubmed: 23048170
Pediatr Surg Int. 2019 Mar;35(3):373-381
pubmed: 30478702
Expert Rev Vaccines. 2018 Dec;17(12):1135-1141
pubmed: 30407079
J Clin Microbiol. 2006 Sep;44(9):3371-3
pubmed: 16954276
J Infect Dis. 2004 Apr 15;189(8):1382-7
pubmed: 15073674
Clin Infect Dis. 2017 Sep 1;65(5):840-850
pubmed: 28444323
J Pediatr. 2006 Oct;149(4):452-60
pubmed: 17011313
Clin Infect Dis. 2014 Jan;58(1):61-8
pubmed: 24092802

Auteurs

Corinne Willame (C)

GSK Vaccines , Wavre, Belgium.

Brigitte Cheuvart (B)

GSK Vaccines , Wavre, Belgium.

Emmanuel Aris (E)

GSK Vaccines , Wavre, Belgium.

Volker Vetter (V)

GSK Vaccines , Wavre, Belgium.

Catherine Cohet (C)

GSK Vaccines , Wavre, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH